id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-N-0194-0003,FDA,FDA-2002-N-0194,"Agency Information Collection Activities; Announcement of OMB Approval; New Drugs and Biological
Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies
Are Not Ethical or Feasible",Notice,Notice of Approval,2003-06-01T04:00:00Z,2003,6,2003-05-21T04:00:00Z,,2025-05-13T09:47:09Z,03-12723,0,0,0900006480495896
FDA-2002-N-0194-0002,FDA,FDA-2002-N-0194,"Agency Information Collection Activities; Submission for OMB Review; Comment Request; New Drug
and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible",Notice,General Notice,2003-03-16T05:00:00Z,2003,3,2003-03-07T05:00:00Z,2003-04-08T03:59:59Z,2025-05-13T09:45:34Z,03-5357,0,0,0900006480495892
FDA-2002-N-0194-0001,FDA,FDA-2002-N-0194,"Agency Information Collection Activities; Proposed Collection; Comment Request; New Drug and
Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible",Notice,General Notice,2002-11-13T05:00:00Z,2002,11,2002-11-13T05:00:00Z,2003-01-14T04:59:59Z,2025-05-13T09:43:12Z,02-28854,0,0,090000648049588f